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Recombinant VLP based human 
vaccines for emerging markets 
Qinjian Zhao
School of Public Health, Xiamen University, China
May 21, 2012 @  Albufeira, Portugal
Outlines
− Production platforms for recombinant VLP based
vaccine
− Pipeline of VLP based vaccines
− First licensed HEV vaccine
− Other VLP based vaccines under development
Production platforms for 
recombinant VLP based vaccine
Cho, H. J., Y. K. Oh, et al. (2011). “Advances in human papilloma virus vaccines: a 
patent review.” Expert Opin Ther Pat.
Pipeline of VLP based vaccines
Preclinical




























First licensed HEV vaccine
2004.11
Approval of Phase I/II
2007.6  









Wu, et al. Human Vaccine, 2012
Geographic distribution of Hepatitis E 
http://www.humenhealth.com/hepatitis













Process optimization / scale-up
R & D of HEV239 vaccine
Much preferred immuno-reactivity of 
patient sera to E2 (over monomeric form) 
• pORF2 forms dimer, or higher order 
assemblies upon over expression
• Sucessful expression of HEV pORF2 
fragment, E2, in E. coli
• Lost immuno-reactivity of E2 dimer 
upon denaturation into monomer
Western Blot
Zhang et al. J Med Virol 2001.
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Dimer
Preferred reactivity of patient sera 
to dimeric form ( E2) of pORF2
Monomer
Acute phase sera Convalescence sera N
• No reactivity to monomer antigen in convalescence sera
• Immunodominant epitopes of HEV pORF2 residing on 
dimeric form
Protection of rhesus monkeys from infection
(immunization with E2)
Zhang et al. J Med Virol 2001.
Identification of two major neutralizing 
epitopes of HEV pORF2
Zhang, et al. Vaccine, 2005
Dimerization of  HEV pORF2
(E2s domain-149aa)
AUC







Structure of HEV pORF2
(E2s domain-149aa)
of E2s(I) (ORF2 455-602)
Li et al. PLoS Pathogens. 2009
 Typical capsid protein folding: 
β-barrel
 Dimerization: strong 
hydrophobic interactions
 Groove region: flexible loops
dimerization interface
Mapping of key residues on E2s
 Dimer interface Immune-predominant 
neutralizing sites







Structure of E2s:8C11 mAb complex
Resolution 1.9 Å
8C11
Total buried area 1763 Å2
Tang et al., PNAS. 2011. 
Antigen surface Vs. antibody aa
8C11 epitope on E2s: Asp496-Thr499, Val510-Leu514 and Asn573-Arg578







Gel filtration by HPLC
(GSW3000xl column)
SDS-PAGE and WB
of p239 vs. E2
• Successive N terminal extension of E2 generated particulate HEV 239,
retaining dimerization capability and major neutralization epitopes.
Li et al. JBC, Vaccine. 2005
Enhanced Immunogenicity of 239
Li et al. Vaccine 2005.
HEV 239 vaccine efficacy in rhesus monkeys
Li et al. Vaccine 2005.
Process flowchart of HEV 239 vaccine
	











Blue: Class D clean area
Green: Class C clean area
Red: locally A/B clean area







QC of p239  vaccine
Product : HEV vaccine Mfg. Date:   Apr 2003
Batch No:  20030401 Pack size: 0.5 ML
S.No Tests Specifications Result
1 Fill volume 0.5 – 0.6 ml Passes
2 Appearance White turbid liquid Whitish turbid  liquid 
3 Identity–ELISA Should identify Identifies
4 Al+++ content Al(OH)3 1.4~1.8 mg / ml 0.56 mg / ml
5 Thiomersal 
content
39.0 – 67.0 µg / ml 50 µg / ml
6 pH 6.1-7.4 6.65
7 Sterility Shall comply Passes
8 Abnormal toxicity Shall comply Passes
9 Bacterial 
endotoxins





Less than 1.5 µg 0.113






















Clinical trials of HEV vaccine
Guangxi, China
Jiangsu, China
Clinical trials of HEV vaccine
Wu, et al. Human Vaccine. 2012
Phase III Clinical trials of HEV vaccine
15 hepatitis E cases 
ALL in placebo group
i.e.
Zhu, et al. Lancet. 2010
Flowchart of surveillance and certification of acute hepaitis E in phase III
100% efficacy against 
hepatitis E 
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Other VLP based vaccines under development
• HPV16/18 bivalent vaccine
• HPV6/11 bivalent vaccine
• HPV16/18/52/58/31/33/45/35/59 9-valent vaccine
• RV quadrivalent vaccine
HPV16/18 bivalent vaccine
 E. coli expression system












































 Comparable neutralizing antibody levels
1 
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Gardasil(HPV16 20µg) Innovax's HPV vaccine(HPV16 20µg) 
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Post=vac (weeks)
Gardasil(HPV18 10µg) Innovax's HPV vaccine(HPV18 10µg) 
HPV6/11 bivalent vaccine
 E. coli expression system




Ongoing efforts on VLP based vaccine
• High-risk type: HPV16/18/52/58/33/31/45/35/59 VLP
• corresponding pseudovirion-based neutralization assay
Ongoing efforts on VLP based 
nano-scale bioparticles
 Rotavirus VLP for 
vaccine
 HBcAg for epitope 
VP6 VLP VP2/6 DLPVP2 CLP
presentation
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Immunogenicity of HPV6/11 bivalent 

















































 Comparable neutralizing antibody levels
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Gardasil(HPV6 7.5µg) Innovax's HPVvaccine(HPV6 7.5µg) 
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Gardasil(HPV11 15µg) Innovax's HPVvaccine(HPV11 15µg) 
